<!DOCTYPE html>
<html lang="en">
	<head>
  		<meta charset="UTF-8">
  		<title>Bio2RDF - Drugbank</title>
		<link href="images/bio2rdf.png" rel="shortcut icon" />
		<link rel="stylesheet" type="text/css" href="css/style.css" media="screen" />
  		<script src="https://code.jquery.com/jquery-3.2.1.min.js"></script>
  		<script src="handlebars-v4.0.10.js"></script>
  		<!--<script src="https://cdnjs.cloudflare.com/ajax/libs/handlebars.js/4.0.10/handlebars.runtime.min.js"></script>-->
	
		<script type="application/ld+json">{
 "@context" : "http://schema.org",
  "id" : "http://bio2rdf.org/drugbank:DB00078",
  "type" : "Drug",
  "clinicalPharmacology" : "Ibritumomab is a murine monoclonal antibody against CD20 that has been radiolabeled with yttrium-90.",
  "cost" : [ {
    "id" : "http://bio2rdf.org/drugbank_resource:d142d3fd24116c4a57fc7ecaac8d4f3e",
    "type" : "DrugCost",
    "costCurrency" : "USD",
    "costPerUnit" : "4200.0",
    "drugUnit" : "Zevalin in-111 kit"
  }, {
    "id" : "http://bio2rdf.org/drugbank_resource:d17f3e51cf6f5e3dad7d547f6d3c0410",
    "type" : "DrugCost",
    "costCurrency" : "USD",
    "costPerUnit" : "37800.0",
    "drugUnit" : "Zevalin y-90 kit"
  } ],
  "description" : "Indium conjugated murine IgG1 kappa monoclonal antibody directed against the CD20 antigen, which is found on the surface of normal and malignant B lymphocytes. Ibritumomab is produced in Chinese hamster ovary cells and is composed of two murine gamma 1 heavy chains of 445 amino acids each and two kappa light chains of 213 amino acids each.",
  "schema:identifier" : "drugbank:DB00078",
  "interactingDrug" : [ "DDI between Ibritumomab and Prasugrel - Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding.", "DDI between Ibritumomab and Sulodexide - May enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to an increased risk of bleeding.", "DDI between Ibritumomab and Naproxen - Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding.", "DDI between Ibritumomab and Levomilnacipran - Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding.", "DDI between Ibritumomab and Anagrelide - Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding.", "DDI between Ibritumomab and Nadroparin - Anticoagulants may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to an increased risk of bleeding.", "DDI between Ibritumomab and Oxaprozin - Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding.", "DDI between Ibritumomab and Tiaprofenic acid - Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding.", "DDI between Ibritumomab and Citalopram - Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding.", "DDI between Ibritumomab and Rivaroxaban - Anticoagulants may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to an increased risk of bleeding.", "DDI between Ibritumomab and Sipuleucel-T - Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.", "DDI between Ibritumomab and Meloxicam - Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding.", "DDI between Ibritumomab and Venlafaxine - Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding.", "DDI between Ibritumomab and Enoxaparin - May enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to an increased risk of bleeding.", "DDI between Ibritumomab and Natalizumab - Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.", "DDI between Ibritumomab and Belimumab - Monoclonal Antibodies may enhance the adverse/toxic effect of Belimumab.", "DDI between Ibritumomab and Ketorolac - Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding.", "DDI between Ibritumomab and Tolmetin - Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding.", "DDI between Ibritumomab and Pimecrolimus - May enhance the adverse/toxic effect of Immunosuppressants.", "DDI between Ibritumomab and Phenindione - May enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to an increased risk of bleeding.", "DDI between Ibritumomab and Ticlopidine - Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding.", "DDI between Ibritumomab and Fondaparinux sodium - May enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to an increased risk of bleeding.", "DDI between Abciximab and Ibritumomab - Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding.", "DDI between Ibritumomab and Ethyl biscoumacetate - May enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to an increased risk of bleeding.", "DDI between Ibritumomab and Nabumetone - Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding.", "DDI between Ibritumomab and Clopidogrel - Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding.", "DDI between Ibritumomab and Dalteparin - May enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to an increased risk of bleeding.", "DDI between Ibritumomab and Escitalopram - Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding.", "DDI between Ibritumomab and Cilostazol - Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding.", "DDI between Ibritumomab and Vorapaxar - Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding.", "DDI between Ibritumomab and Indomethacin - Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding.", "DDI between Ibritumomab and Piroxicam - Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding.", "DDI between Ibritumomab and Fluoxetine - Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding.", "DDI between Trastuzumab and Ibritumomab - May enhance the neutropenic effect of Immunosuppressants.", "DDI between Ibritumomab and Edetic Acid - May enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to an increased risk of bleeding.", "DDI between Ibritumomab and Roflumilast - May enhance the immunosuppressive effect of Immunosuppressants.", "DDI between Ibritumomab and Heparin - May enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to an increased risk of bleeding.", "DDI between Bivalirudin and Ibritumomab - Anticoagulants may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to an increased risk of bleeding.", "DDI between Ibritumomab and Danaparoid - Anticoagulants may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to an increased risk of bleeding.", "DDI between Ibritumomab and Ibuprofen - Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding.", "DDI between Ibritumomab and Tinzaparin - Anticoagulants may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to an increased risk of bleeding.", "DDI between Ibritumomab and Treprostinil - May enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to an increased risk of bleeding.", "DDI between Ibritumomab and Leflunomide - Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.", "DDI between Ibritumomab and Sertraline - Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding.", "DDI between Ibritumomab and Tirofiban - Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding.", "DDI between Ibritumomab and Milnacipran - Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding.", "DDI between Ibritumomab and Fluvoxamine - Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding.", "DDI between Ibritumomab and Sulindac - Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding.", "DDI between Ibritumomab and Denosumab - May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.", "DDI between Ibritumomab and Ticagrelor - Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding.", "DDI between Ibritumomab and Acetylsalicylic acid - Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding.", "DDI between Ibritumomab and Apixaban - Anticoagulants may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to an increased risk of bleeding.", "DDI between Ibritumomab and Dicoumarol - May enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to an increased risk of bleeding.", "DDI between Ibritumomab and Duloxetine - Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding.", "DDI between Ibritumomab and Dipyridamole - Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding.", "DDI between Ibritumomab and Dabigatran etexilate - Anticoagulants may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to an increased risk of bleeding.", "DDI between Ibritumomab and Floctafenine - Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding.", "DDI between Ibritumomab and Citric Acid - May enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to an increased risk of bleeding.", "DDI between Ibritumomab and Warfarin - May enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to an increased risk of bleeding.", "DDI between Ibritumomab and Mefenamic acid - Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding.", "DDI between Ibritumomab and Desvenlafaxine - Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding.", "DDI between Ibritumomab and Acenocoumarol - May enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to an increased risk of bleeding.", "DDI between Ibritumomab and Argatroban - Anticoagulants may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to an increased risk of bleeding.", "DDI between Ibritumomab and Vilazodone - Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding.", "DDI between Ibritumomab and Diflunisal - Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding.", "DDI between Ibritumomab and Paroxetine - Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding.", "DDI between Ibritumomab and Phenprocoumon - May enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to an increased risk of bleeding.", "DDI between Ibritumomab and Etodolac - Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding.", "DDI between Eptifibatide and Ibritumomab - Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding.", "DDI between Ibritumomab and Clozapine - Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for agranulocytosis may be increased.", "DDI between Ibritumomab and Ketoprofen - Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding.", "DDI between Ibritumomab and Tofacitinib - Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.", "DDI between Ibritumomab and Fenoprofen - Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding." ],
  "legalStatus" : "Approved",
  "mechanismOfAction" : "The Fab segment of the antibody targets the CD20 epitope on B-cells, allowing the radioactive yttrium to destroy the cell via production of beta particles.",
  "name" : "Ibritumomab",
  "nonProprietaryName" : [ "radiolabeled murine anti-CD20", "Ig gamma-2A chain C region, membrane-bound form" ],
  "sameAs" : [ "http://www.drugs.com/cdi/ibritumomab-tiuxetan-with-indium-111.html", "http://www.rxlist.com/cgi/generic3/zevalin.htm", "http://www.drugbank.ca/drugs/DB00078" ],
  "schema:url" : "http://bio2rdf.org/drugbank:DB00078"
}</script>
	</head>

	<body>
		<br/><br/>
		
		<div id="all">
	 		<div id="main" style="text-align: center;">
	 			<div style="height: 20%;">&nbsp;</div>
	 			<img alt="Drugbank" src="images/drugbank.png" />
	 			<div id="main" style="text-align: center;">
	 				<em>Bio2RDF Drugbank Data</em>
				</div>

				<br/><br/>

			</div>

			<div id="contents">
				<script type="text/javascript">

				var templateCode = "<table><tbody><tr><td class='dataframeKey'>Drug Name</td><td>{{name}}</td></tr><tr><td class='dataframeKey'>Description</td><td>{{description}}</td></tr><tr><td class='dataframeKey'>Identifier</td><td>{{schema:identifier}}</td></tr><tr><td class='dataframeKey'>Non-Proprietary Names</td><td><ul>{{#each nonProprietaryName}}<li>{{this}}</li>{{else}}{{nonProprietaryName}}{{/each}}</ul></td></tr><tr><td class='dataframeKey'>Proprietary Name</td><td>{{proprietaryName}}</td></tr><tr><td class='dataframeKey'>Drug Classes</td><td><ul>{{#each drugClass}}<li>{{this}}</li>{{else}}{{drugClass}}{{/each}}</ul></td></tr><tr><td class='dataframeKey'>Clinical Pharmacology</td><td>{{clinicalPharmacology}}</td></tr><tr><td class='dataframeKey'>Manufacturer</td><td>{{#with manufacturer}}{{name}}{{/with}}</td></tr><tr><td class='dataframeKey'>Mechanism of Action</td><td>{{mechanismOfAction}}</td></tr><tr><td class='dataframeKey'>Food Warning</td><td>{{foodWarning}}</td></tr><tr><td class='dataframeKey'>URL</td><td><a href='{{schema:url}}'>{{schema:url}}</a></td></tr><tr><td class='dataframeKey'>Costs</td><td>{{#if cost.length}}<ul>{{#each cost}}<li>{{#with this}}{{drugUnit}} - {{costPerUnit}}{{costCurrency}}{{/with}}</li>{{/each}}</ul>{{else}}{{#with cost}}{{drugUnit}} - {{costPerUnit}}{{costCurrency}}{{/with}}{{/if}}</td></tr><tr><td class='dataframeKey'>Available Strength</td><td>{{#if availableStrength.length}}<ul>{{#each availableStrength}}<li>{{this.description}}</li>{{/each}}</ul>{{else}}{{#with availableStrength}}{{description}}{{/with}}{{/if}}</td></tr><tr><td class='dataframeKey'>Dosage Forms</td><td><ul>{{#each dosageForm}}<li>{{this}}</li>{{else}}{{dosageForm}}{{/each}}</ul></td></tr><tr><td class='dataframeKey'>Administration Route</td><td><ul>{{#each administrationRoute}}<li>{{this}}</li>{{else}}{{administrationRoute}}{{/each}}</ul></td></tr><tr><td class='dataframeKey'>Interacting Drugs</td><td><ul>{{#each interactingDrug}}<li>{{this}}</li>{{else}}{{interactingDrug}}{{/each}}</ul></td></tr><tr><td class='dataframeKey'>Legal Statuses</td><td><ul>{{#each legalStatus}}<li>{{this}}</li>{{else}}{{legalStatus}}{{/each}}</ul></td></tr><tr><td class='dataframeKey'>Same As</td><td><ul>{{#each sameAs}}<li><a href='{{this}}'>{{this}}</a></li>{{else}}<a href='{{sameAs}}'>{{sameAs}}</a>{{/each}}</ul></td></tr></tbody></table>";
				var template = Handlebars.compile(templateCode);

				$.getJSON("jsonld/DB00078.json", function(data) {
			    	document.getElementById("contents").innerHTML += template(data);
				});
		
				</script>
			</div>
		</div>
	</body>
</html>